Post-authorisation assessment of orphan drugs

Lancet. 2015 Nov 14;386(10007):1940-1941. doi: 10.1016/S0140-6736(15)00827-2. Epub 2015 Nov 13.

Authors

Carla E M Hollak¹, Marieke Biegstraaten², Marcel Levi³, Rob Hagendijk⁴

Affiliations

¹ Department of Internal Medicine, Division of Endocrinology and Metabolism, Academic Medical Center, Amsterdam, Netherlands. Electronic address: c.e.hollak@amc.nl.
² Department of Internal Medicine, Division of Endocrinology and Metabolism, Academic Medical Center, Amsterdam, Netherlands.
³ Academic Medical Center, Amsterdam, Netherlands.
⁴ Amsterdam Institute for Social Science Research, University of Amsterdam, Amsterdam, Netherlands.

PMID: 26841744
DOI: 10.1016/S0140-6736(15)00827-2

No abstract available

Publication types

Letter

MeSH terms

Drug Approval / organization & administration*
European Union
Fabry Disease / drug therapy
Humans
Orphan Drug Production*
Rare Diseases / drug therapy